OPKO Health (OPK) Earnings Date & Reports

Key Takeaways

• OPKO Health reported a third-quarter 2026 GAAP (Generally Accepted Accounting Principles) loss of $0.05 per share, narrower than the consensus estimate of a $0.07 loss.
• Continuing operations revenue grew 16% year over year to $65.4 million, driven by higher Lilly royalties, Rayaldee sales, and international growth.
• BioReference Health is now classified as discontinued operations following the announced $722 million asset sale to Labcorp.
• The Global Products segment swung to $6.0 million in operating income, versus a $1.2 million operating loss a year earlier.
• Cash, cash equivalents and restricted cash ended the quarter at $403.2 million, supported by a $125 million royalty financing.
• OPKO repurchased 7.05 million shares for approximately $10.6 million during the quarter.
• For more context on the ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover fresh trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

OPKO Health is in the middle of a deliberate strategic transformation. With the announced sale of select BioReference Health assets to Labcorp for approximately $722 million in cash, the company is exiting the clinical laboratory business to become a focused biopharmaceutical company built around its Global Products segment and an Innovative Biotech pipeline. This report is the first in which BioReference is presented as discontinued operations, meaning investors must reassess the company's true revenue base and profitability profile. The results also signal whether OPKO's remaining businesses, particularly Rayaldee and royalty streams from partners such as Lilly and Pfizer, can fund the company's expanding research and development efforts without additional dilution.

Reported Results

For the third quarter of 2026, OPKO Health reported a GAAP net loss of $0.05 per share, beating the consensus estimate of a $0.07 loss. Consolidated continuing operations revenue rose 16% to $65.4 million from $56.4 million in the prior-year quarter, while the operating loss narrowed to $31.4 million from $33.6 million.

Revenue reflects only the businesses OPKO will retain after closing the Labcorp transaction. The Global Products segment grew to $48.4 million from $39.4 million, with Rayaldee revenue climbing to $8.6 million from $7.5 million and licensing, collaboration and other revenue rising to $6.6 million from $1.8 million, including $5.8 million in royalties from Lilly. The segment posted $6.0 million in operating income versus a $1.2 million loss a year ago. The Innovative Biotech segment generated $17.0 million in revenue, flat year over year, while its operating loss widened to $26.8 million from $22.5 million as research and development investment increased. Discontinued operations, reflecting BioReference, generated $71.8 million in revenue, down from $95.2 million a year earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like OPK across the biotech and healthcare landscape, the screener offers a streamlined way to surface comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Investor attention around this earnings event centered less on the headline numbers and more on the strategic repositioning of the company. Because BioReference was reclassified into discontinued operations, the reported revenue base is now smaller, which can make direct year-over-year and consensus comparisons less intuitive. The narrower-than-expected loss and the swing to profitability in Global Products were viewed as encouraging, while the widening operating loss in Innovative Biotech underscores the rising cost of advancing the ModeX pipeline. Sentiment is likely to remain tied to the completion of the Labcorp transaction and the pace of clinical milestones rather than near-term bottom-line results.

Forward Outlook and Key Factors to Monitor

The most significant item on the horizon is the closing of the Labcorp transaction, which is subject to regulatory approvals and customary conditions. The deal includes roughly $722 million in cash consideration at closing, plus up to $150 million in additional payments over up to ten years tied to 4Kscore sales. This capital is expected to fund OPKO's pipeline and potentially accelerate shareholder returns.

Investors should also watch the clinical development calendar. ModeX continues to advance several programs, including MDX2001 and MDX2003, its tetraspecific T-cell engagers, with subcutaneous dosing cohorts expected in late 2026 or 2027. The company's first in vivo CAR T (chimeric antigen receptor T-cell) program, MDX3001, is targeting first-in-human studies in mid-2027, initially in autoimmune disease.

On the commercial side, Rayaldee and international pharmaceutical operations provide recurring revenue, while royalty streams from NGENLA and Lilly's mazdutide offer non-dilutive cash flow. Key risks include the pace of research and development spending, execution of the Labcorp transition, and the outcome of ongoing litigation, including the Israeli tax assessment. Balanced against these factors is a strengthened balance sheet, with $403.2 million in cash and restricted cash at quarter-end and an active share repurchase program with approximately $84.3 million remaining under its authorization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations